AZD1236

DRUG5 trials

Sponsors

AstraZeneca, University of Edinburgh

Conditions

Chronic Obstructive Pulmonary DiseaseCystic FibrosisFibrosisHealthy VolunteerLung Cancer

Early Phase 1

Imaging FIB ONE in the Human Lung Using Endomicroscopy

CompletedNCT02604862

University of EdinburghFibrosis, Lung Cancer

Start: 2016-05-31End: 2018-09-30Updated: 2020-02-13

Phase 1

Investigate the Safety Tolerability and Pharmacokinetics of Multiple Doses of AZD1236

CompletedNCT00767052

AstraZenecaHealthy Volunteer

Start: 2008-09-30End: 2008-12-31Updated: 2009-06-30

Phase 2

A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients

CompletedNCT00758706

AstraZenecaChronic Obstructive Pulmonary Disease

Start: 2008-09-30End: 2009-05-31Updated: 2015-04-16

Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients

CompletedNCT00758459

AstraZenecaChronic Obstructive Pulmonary Disease

Start: 2008-09-30End: 2009-03-31Updated: 2011-08-19

Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis

WithdrawnNCT00812045

AstraZenecaCystic Fibrosis

Start: 2009-12-31End: 2010-08-31Target: 44Updated: 2009-05-06